<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Notch signaling pathway has been shown to be upregulated in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and important for the self-renewal of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated the efficacy of PF-03084014, a Î³-secretase inhibitor, in combination with irinotecan to identify the effects of treatment on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence and the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-initiating population in our <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> preclinical explant model </plain></SENT>
<SENT sid="2" pm="."><plain>The combination of PF-03084014 and irinotecan had the greatest effect at reducing <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> on four <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> when compared with treatment with PF-03084014 or irinotecan alone </plain></SENT>
<SENT sid="3" pm="."><plain>The combination significantly reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence in two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> explants (CRC001 and CRC036) after treatment was discontinued </plain></SENT>
<SENT sid="4" pm="."><plain>Both of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> exhibited elevated baseline levels of Notch pathway activation as well as an increase in NOTCH1 gene copy number when compared with the two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> explants (CRC026 and CRC027) where <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> reappeared quickly after termination of treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Isolation and injection of <z:chebi fb="1" ids="17478">aldehyde</z:chebi> dehydrogenase (ALDH(+) and ALDH(-)) cells in an in vivo explant model demonstrated that the ALDH(+) cell population were tumorigenic </plain></SENT>
<SENT sid="6" pm="."><plain>Evaluation of the ALDH(+) cells after 28 days of treatment showed that the combination reduced the ALDH(+) population in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that did not regrow </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, ALDH(+) cells from CRC001 and CRC027 were injected in vivo and treated immediately for 28 days </plain></SENT>
<SENT sid="8" pm="."><plain>Two months after treatment, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were evident in the combination treatment group for CRC027 but not for CRC036 </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicate the combination of PF-03084014 and irinotecan may be effective in reducing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> exhibit elevated levels of the Notch pathway </plain></SENT>
</text></document>